共 8 条
[4]
10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal[J] . Daniel Kurnik,Ronen Loebstein,Hillel Halkin,Eva Gak,Shlomo Almog.Pharmacogenomics . 2009 (12)
[5]
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients[J] . Sheng-Wen Huang,Hai-Sheng Chen,Xian-Qun Wang,Ling Huang,Ding-Li Xu,Xiao-Jia Hu,Zhi-Hui Huang,Yong He,Kai-Ming Chen,Dao-Kang Xiang,Xiao-Ming Zou,Qiang Li,Li-Qin Ma,Hao-Fei Wang,Bao-Lin Chen,Liang Li,Yan-Kai Jia,Xiang-Min Xu.Pharmacogenetics and Genomics . 2009 (3)
[7]
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues[J] . Brian F. Gage,Lawrence J. Lesko.Journal of Thrombosis and Thrombolysis . 2008 (1)
[8]
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients[J] . Liyan Miao,Jian Yang,Chenrong Huang,Zhenya Shen.European Journal of Clinical Pharmacology . 2007 (12)